Cempra (CEMP) – FDA News
-
Melinta Therapeutics Says its Topical Radezolid Was Well Tolerated in Phase 1 Study for Treatment of Acne (CEMP)
-
Cempra (CEMP) Announces Eight Presentations at ASM Microbe
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to CEMP Stock Lookup